Visualization and characterization of GB virus-C particles: evidence for a nucleocapsid.

Abstract:

:GB virus type C (GBV-C) is a member of the hepacivirus genus within the Flaviviradae. Persistent GBV-C infection is common in humans, yet it remains unclear if GBV-C causes any disease. Although GBV-C infection has been associated with acute non-A to non-E post-transfusion hepatitis, it does not appear to cause chronic hepatitis. GBV-C is closely related to hepatitis C virus (HCV), but indirect evidence suggests that it does not encode a core protein at the amino terminus of the open reading frame (ORF). This has led to speculation that GBV-C does not have a nucleocapsid. We evaluated the buoyant density of GBV-C, and found very low density particles consistent with virions, and intermediate density particles consistent with nucleocapsids in GBV-C-infected people. In addition, electron microscopy demonstrated an apparent nucleocapsid within an enveloped particle. Although these biophysical data strongly suggest that GBV-C utilizes a nucleocapsid, they do not indicate the origin of the protein content of this particle. To assess this, we evaluated patient plasma for reactivity with a synthetic oligopeptide representing a conserved region near the amino terminus of the predicted ORF. Specific antibody was detected in some individuals, similar to data of Feucht et al. who identified antibody against a recombinant core protein in GBV-C-infected people. These data indicate that GBV-C particles contain nucleocapsids. At least in some patients, the region upstream of the GBV-C E1 protein coding region appears to be expressed, and this region may represent the structural protein of the nucleocapsid.

journal_name

J Viral Hepat

authors

Xiang J,Daniels KJ,Soll DR,Schmidt WN,Labrecque DR,Stapleton JT

doi

10.1046/j.1365-2893.1999.00003.x

subject

Has Abstract

pub_date

1999-07-01 00:00:00

pages

16-22

eissn

1352-0504

issn

1365-2893

pii

jvh003

journal_volume

6 Suppl 1

pub_type

杂志文章,评审
  • Susceptibility to active decompensated cirrhosis is associated with polymorphisms of intercellular adhesion molecule-1 (ICAM-1) in chronic HBV carriers.

    abstract::Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the pathogenesis of viral hepatitis B. Several inflammatory diseases are associated with distinct polymorphisms of the ICAM-1 gene. The aims of this study were to analyse the association of ICAM-1 polymorphisms G241R and K469E with susceptibility to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00931.x

    authors: Zhang XQ,Hong XJ,Bai XJ

    更新日期:2008-03-01 00:00:00

  • Occult hepatitis C virus infection in type II mixed cryoglobulinaemia.

    abstract::Mixed cryoglobulinaemia, when not secondary to other well-defined immunological disorders, is commonly associated with hepatitis C virus (HCV) infection. However, a minority of cases lack evidence of HCV infection and are, therefore, defined as 'true essential' mixed cryoglobulinaemias. We thoroughly investigated thre...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00462.x

    authors: Casato M,Lilli D,Donato G,Granata M,Conti V,Del Giudice G,Rivanera D,Scagnolari C,Antonelli G,Fiorilli M

    更新日期:2003-11-01 00:00:00

  • The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.

    abstract::We describe the epidemiology of hepatitis B virus (HBV) infection among women of reproductive age residing in areas of China that are highly endemic for chronic HBV, and provide evidence useful for decision-makers to guide strategies for preventing mother-to-child transmission of HBV, and assess the impact of perinata...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12757

    authors: Zheng H,Cui FQ,Wang FZ,Huang LF,Shao XP,Du JF,Li J,Zhou Y,Zheng HZ,Zhuo JT,Zeng XX,Zhang GM,Miao N,Sun XJ,Liang XF,Luo HM

    更新日期:2018-01-01 00:00:00

  • Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials.

    abstract::The efficacy of monotherapy with interferon (IFN) (conventional or pegylated IFN) in dialysis patients with chronic hepatitis C remains unclear, although a number of clinical trials have been published addressing this issue. The aim of the study was to evaluate the efficacy and safety of monotherapy by conventional or...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,meta分析

    doi:10.1111/j.1365-2893.2007.00907.x

    authors: Fabrizi F,Dixit V,Messa P,Martin P

    更新日期:2008-02-01 00:00:00

  • Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.

    abstract::It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analysed data from patie...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12723

    authors: Kim GA,Han S,Kim HD,An J,Lim YS

    更新日期:2017-11-01 00:00:00

  • Increased serum levels of macrophage inflammatory protein-3alpha in chronic viral hepatitis: prognostic importance of macrophage inflammatory protein-3alpha during interferon therapy in chronic hepatitis C.

    abstract::Increased infiltration of lymphocytes and induction of damage and destruction of hepatocytes by these lymphocytes are characteristic features of chronic viral hepatitis. As chemokines attract lymphocytes to inflamed tissues, we studied macrophage inflammatory protein (MIP)-3alpha, a CC chemokine, in chronic viral hepa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2002.00354.x

    authors: Yamauchi K,Akbar SM,Horiike N,Michitaka K,Onji M

    更新日期:2002-05-01 00:00:00

  • Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

    abstract::Chronic hepatitis C virus (HCV) infection eventually leads to cirrhosis in 20-30% of patients and to hepatocellular carcinoma (HCC) in 1-5% of patients. Rates of sustained virological response with standard interferon-alpha (IFN-alpha) are low in patients without cirrhosis (generally < 20%) and are even lower in those...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00229.x

    authors: Zeuzem S

    更新日期:2000-09-01 00:00:00

  • Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.

    abstract::High rates (~25%) of developing chronic hepatitis B virus (HBV) infection (hepatitis B surface antigen (HBsAg)-positive for > 6 months following infection) have been observed in people who use drugs (PWUD) and men who have sex with men (MSM). We aimed to estimate the frequency of delayed HBsAg seroclearance, along wit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13205

    authors: van Santen DK,Boyd A,Bruisten S,Sonder GJ,Prins M,van Houdt R

    更新日期:2020-01-01 00:00:00

  • Long-term interferon-alpha treatment of children with chronic hepatitis delta: a multicentre study.

    abstract::We assessed the efficacy of prolonged interferon-alpha (IFN) therapy in children with chronic hepatitis caused by hepatitis delta virus (HDV) by treating 26 paediatric cases with IFN-alpha 2b (5 MU m-2, then 3 MU m-2 three times weekly for 12 (medium-term group MTG) or 24 months (long-term group, LTG). Compliance and ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1111/j.1365-2893.1996.tb00002.x

    authors: Di Marco V,Giacchino R,Timitilli A,Bortolotti F,Crivellaro C,Calzia R,Iannuzzi C,Prestileo T,Vajro P,Nebbia G,Stringhi C,Rosina F,Biassoni D,Callea F,Rizzetto M,Craxi A

    更新日期:1996-05-01 00:00:00

  • Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.

    abstract::This study investigated the molecular and pharmacokinetic mechanisms of the enhanced antiviral efficacy associated with pegylated interferon (PEG-IFN) alpha-2b and ribavirin. The study involved comparing the expression of serial double-stranded RNA-activated protein kinase (PKR) before and during treatment in 26 PEG-I...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2893.2006.00803.x

    authors: Asahina Y,Izumi N,Umeda N,Hosokawa T,Ueda K,Doi F,Tsuchiya K,Nakanishi H,Matsunaga K,Kitamura T,Kurosaki M,Uchihara M,Higaki M,Miyake S

    更新日期:2007-06-01 00:00:00

  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

    abstract::Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2011.01560.x

    authors: Mederacke I,Yurdaydin C,Großhennig A,Erhardt A,Cakaloglu Y,Yalcin K,Gurel S,Zeuzem S,Zachou K,Chatzikyrkou C,Bozkaya H,Dalekos GN,Manns MP,Wedemeyer H,Hep-Net\/International Delta Hepatitis Study Group.

    更新日期:2012-06-01 00:00:00

  • The role of the hepatitis viruses in cholangiocarcinoma.

    abstract::Cholangiocarcinoma is the second most common liver cancer in the world. The aetiology of the disease is diverse incorporating a variety of conditions leading to biliary stasis, biliary and liver inflammation, but a large number of cases still occur in the absence of established risk factors. Its incidence and mortalit...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12093

    authors: Ralphs S,Khan SA

    更新日期:2013-05-01 00:00:00

  • Adefovir serum levels do not differ between responders and nonresponders.

    abstract::Primary or secondary failure of adefovir dipivoxil (ADV) therapy of chronic hepatitis B is not infrequent. The reasons for suboptimal responses are not well defined. In HIV and hepatitis C virus infection, failure of antiviral drug therapy has been linked with low blood drug levels. We have studied 20 well-defined pat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01404.x

    authors: Deterding K,Naesens L,Buti M,Janssen H,Kirschner J,Guerrero A,Reijnders J,Neyts J,Zoulim F,Wedemeyer H

    更新日期:2011-07-01 00:00:00

  • Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.

    abstract::In previous hepatitis C virus (HCV) treatment studies, Black patients not only had a lower sustained viral response (SVR) rate to interferon and ribavirin (RBV) than non-Black patients but also a higher frequency of HCV genotype 1 (GT-1) infection. The aim of this community-based study was to determine whether Black p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2005.00682.x

    authors: Bräu N,Bini EJ,Currie S,Shen H,Schmidt WN,King PD,Ho SB,Cheung RC,Hu KQ,Anand BS,Simon FR,Aytaman A,Johnson DP,Awad JA,Ahmad J,Mendenhall CL,Pedrosa MC,Moseley RH,Hagedorn CH,Waters B,Chang KM,Morgan TR,Rossi

    更新日期:2006-04-01 00:00:00

  • Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

    abstract::We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, o...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12684

    authors: Janjua NZ,Islam N,Wong J,Yoshida EM,Ramji A,Samji H,Butt ZA,Chong M,Cook D,Alvarez M,Darvishian M,Tyndall M,Krajden M

    更新日期:2017-08-01 00:00:00

  • A multi-centre study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy.

    abstract::The risk of developing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is reduced by antiviral therapy. Here, we evaluated the chronological trends in HCC development risk starting in 2007, when entecavir reimbursement was first initiated in South Korea. Treatment-naïve patients with chronic hepatitis B...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13384

    authors: Kim SU,Chon YE,Seo YS,Lee HW,Lee HA,Kim MN,Min IK,Park JY,Kim DY,Ahn SH,Tak WY,Kim BK,Park SY

    更新日期:2020-12-01 00:00:00

  • Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.

    abstract::Hepatitis C virus (HCV) chronically infects about 200 million individuals worldwide and leads to severe liver and lymphatic diseases. HCV circulates in the serum, associated with apoB-containing lipoproteins. Platelet-activating factor (PAF), a pro-inflammatory mediator, is mainly modulated by plasma PAF-acetylhydrola...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00766.x

    authors: Caini P,Guerra CT,Giannini C,Giannelli F,Gragnani L,Petrarca A,Solazzo V,Monti M,Laffi G,Zignego AL

    更新日期:2007-01-01 00:00:00

  • High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

    abstract::To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe p...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13035

    authors: Schulkind J,Stephens B,Ahmad F,Johnston L,Hutchinson S,Thain D,Ward Z,Vickerman P,Hickman M,Dillon JF

    更新日期:2019-05-01 00:00:00

  • An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate.

    abstract::In patients with chronic hepatitis B (CHB), long-term effects of tenofovir disoproxil fumarate (TDF) on renal function have been controversial. This study aimed to analyse the real-world long-term effects of TDF on renal function in Korean patients with CHB. We analysed a cohort of 640 treatment-naïve patients with CH...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13222

    authors: Lim TS,Lee JS,Kim BK,Lee HW,Jeon MY,Kim SU,Park JY,Kim DY,Han KH,Ahn SH

    更新日期:2020-03-01 00:00:00

  • Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.

    abstract::It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13058

    authors: Kong Y,Sun Y,Zhou J,Wu X,Chen Y,Piao H,Lu L,Ding H,Nan Y,Jiang W,Xu Y,Xie W,Li H,Feng B,Shi G,Chen G,Li H,Zheng H,Cheng J,Wang T,Liu H,Lv F,Shao C,Mao Y,Sun J,Chen T,Han T,Han Y,Wang L,Ou X,Zha

    更新日期:2019-05-01 00:00:00

  • Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.

    abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12427

    authors: Ogawa E,Furusyo N,Dohmen K,Kajiwara E,Kawano A,Nomura H,Takahashi K,Satoh T,Azuma K,Nakamuta M,Koyanagi T,Kotoh K,Shimoda S,Hayashi J,Kyushu University Liver Disease Study (KULDS) Group.

    更新日期:2015-12-01 00:00:00

  • Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.

    abstract::Extremely low levels of serum hepatitis C virus (HCV) RNA can be detected by COBAS TaqMan HCV test. To investigate whether the COBAS TaqMan HCV test is useful for measuring rapid virological response (RVR) and early virological response (EVR) to predict sustained virological response (SVR), we compared the virological...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01409.x

    authors: Kanda T,Imazeki F,Yonemitsu Y,Mikami S,Takada N,Nishino T,Takashi M,Tsubota A,Kato K,Sugiura N,Tawada A,Wu S,Tanaka T,Nakamoto S,Mikata R,Tada M,Chiba T,Kurihara T,Arai M,Fujiwara K,Kanai F,Yokosuka O

    更新日期:2011-07-01 00:00:00

  • Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.

    abstract::Transient elastometry (TE) could provide a more accurate evaluation of the frequency and risk factors of liver fibrosis in hepatitis C virus (HCV) infection than that based on biopsy. The aim of this study was to assess the prevalence of and factors associated with significant liver fibrosis in a large population of H...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2009.01229.x

    authors: Pineda JA,González J,Ortega E,Tural C,Macías J,Griffa L,Burgos A,Grafihco Study Team.

    更新日期:2010-10-01 00:00:00

  • A systematic analysis of the predicted human La protein targets identified a hepatitis B virus infection signature.

    abstract::The human La (hLa) protein functions in RNA metabolism and is activated by casein kinase 2 (CK2) phosphorylation. Hepatitis B virus (HBV) can exploit hLa to stabilize its RNA and promote its pathogenesis. To enhance our knowledge of host molecular pathways involved in HBV pathogenesis, a bioinformatic approach was use...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01626.x

    authors: Tang J,Zhang ZH,Liu GL

    更新日期:2013-01-01 00:00:00

  • High prevalence of hantavirus infection in a group of Chinese patients with acute hepatitis of unknown aetiology.

    abstract::In southwestern China, small but substantial numbers of patients with acute hepatitis were found without known hepatropic viral infections (hepatitis A, B, C, D or E, cytomegalovirus, Epstein-Barr virus) and were receiving no hepatotoxic drugs. Prevalence of antibodies, both neutralizing and specific immunoglobulin (I...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1997.00140.x

    authors: Meng G,Lan Y,Nakagawa M,Maehara T,Mitani K,Tomiyama T,Che XG,Ohkubo A

    更新日期:1997-07-01 00:00:00

  • Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.

    abstract:SUMMARY:Treatment of hepatitis C virus (HCV) infection with interferon (IFN)-alpha, as monotherapy or in combination with ribavirin, is associated with significant side-effects including weight loss. The aim of our study was to describe the evolution of body weight during combination antiviral treatment and to examine ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00637.x

    authors: Seyam MS,Freshwater DA,O'Donnell K,Mutimer DJ

    更新日期:2005-09-01 00:00:00

  • Oxidative burst response of neutrophils primed with PreS1 antigen of hepatitis B virus in patients with chronic hepatitis B and convalescents.

    abstract::The pathogenesis of liver damage in the course of hepatitis B virus (HBV) infection depends on the host's specific and non-specific immune response to various viral antigens. The role of polymorphonuclear neutrophils (PMN) in the natural immune reaction and during secondary microbial infections is well documented. Inc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00101.x

    authors: Sułowska Z,Pietruszynski R,Dworniak D,Tchórzewski H,Sidorkiewicz M

    更新日期:1996-11-01 00:00:00

  • Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

    abstract::Hepatitis C virus (HCV) is commonly transmitted by intravenous drug use (IDU) but drug users are under represented in many treatment cohorts, this is because of the assumption of lowered treatment success. We assessed HCV treatment outcomes in active intravenous drug users and patients on opiate substitution therapy. ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01446.x

    authors: Jafferbhoy H,Miller MH,Dunbar JK,Tait J,McLeod S,Dillon JF

    更新日期:2012-02-01 00:00:00

  • Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia.

    abstract::Assessment and treatment for hepatitis C virus (HCV) in the community remains low. We evaluated factors associated with HCV specialist assessment and treatment in a cross-sectional study to evaluate treatment considerations in a sample of 634 participants with self-reported HCV infection in New South Wales, Australia....

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01370.x

    authors: Grebely J,Bryant J,Hull P,Hopwood M,Lavis Y,Dore GJ,Treloar C

    更新日期:2011-04-01 00:00:00

  • Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.

    abstract::High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic h...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2002.00370.x

    authors: Di Marco V,Ferraro D,Almasio P,Vaccaro A,Parisi P,Cappello M,Cino N,Di Stefano R,Craxì A

    更新日期:2002-09-01 00:00:00